Cyclooxygenase2 inhibitors and cardiovascular risk in a nationwide cohort study after the withdrawal of rofecoxib

http://www.medworm.com/index.php?rid=6272281&cid=c_64_7_f&fid=29161&url=http%3A%2F%2Feurheartj.oxfordjournals.org%2Fcgi%2Fcontent%2Fshort%2F33%2F15%2F1928%3Frss%3D1

Comments are closed.